• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在孕期使用Abrysvo疫苗预防婴儿呼吸道合胞病毒感染：一项综述

Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review.

作者信息

Patel Dhanvi, Chawla Jyotsna, Blavo Cyril

机构信息

Department of Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA.

Department of Foundational Sciences, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA.

出版信息

Cureus. 2024 Aug 31;16(8):e68349. doi: 10.7759/cureus.68349. eCollection 2024 Aug.

DOI:10.7759/cureus.68349
PMID:39355078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442887/
Abstract

The FDA's approval of Pfizer's new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events. It aims to inform healthcare providers about this vital method for safeguarding infant respiratory health through maternal immunization.

摘要

美国食品药品监督管理局（FDA）批准辉瑞公司的新型呼吸道合胞病毒（RSV）预融合（preF）疫苗Abrysvo，通过预防最脆弱人群的下呼吸道感染，这在婴儿健康和福祉方面标志着一个关键的里程碑。该疫苗已被批准用于妊娠32至36周的孕妇以及60岁以上的老年人。本综述探讨了Abrysvo疫苗，详细介绍了其作用机制、疗效、安全性和不良事件。其目的是让医疗保健提供者了解通过母体免疫来保护婴儿呼吸道健康的这一重要方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe76/11442887/e2c9eacbbce7/cureus-0016-00000068349-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe76/11442887/9c55d99bb94c/cureus-0016-00000068349-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe76/11442887/e2c9eacbbce7/cureus-0016-00000068349-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe76/11442887/9c55d99bb94c/cureus-0016-00000068349-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe76/11442887/e2c9eacbbce7/cureus-0016-00000068349-i02.jpg

相似文献

1
Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review.在孕期使用Abrysvo疫苗预防婴儿呼吸道合胞病毒感染：一项综述
Cureus. 2024 Aug 31;16(8):e68349. doi: 10.7759/cureus.68349. eCollection 2024 Aug.
2
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
3
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.二价 RSVpreF 母传疫苗预防日本婴儿 RSV 疾病的疗效和安全性：来自关键、随机、3 期 MATISSE 试验的亚组分析。
Vaccine. 2024 Sep 17;42(22):126041. doi: 10.1016/j.vaccine.2024.06.009. Epub 2024 Jun 8.
4
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
5
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.呼吸道合胞病毒融合前 F 亚单位疫苗：首个保护婴儿的母体疫苗的批准。
Paediatr Drugs. 2023 Nov;25(6):729-734. doi: 10.1007/s40272-023-00598-3.
6
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.孕期接种呼吸道合胞病毒疫苗以改善婴儿结局。
Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2.
7
RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.RSV 融合前 F 蛋白为基础的母体疫苗-早产和其他结局。
N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478.
8
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024.母亲接种呼吸道合胞病毒疫苗和 8 月龄以下婴儿接种呼吸道合胞病毒抗体（Nirsevimab）-美国，2024 年 4 月。
MMWR Morb Mortal Wkly Rep. 2024 Sep 26;73(38):837-843. doi: 10.15585/mmwr.mm7338a2.
9
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.在母亲及其婴儿中进行的一种呼吸道合胞病毒疫苗（RSVPreF3）的安全性和免疫原性的 2 期随机试验。
J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024.
10
Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization.对呼吸道合胞病毒（RSV）疫苗接种的前瞻性态度：约旦年轻女性中一份调查问卷工具在疫苗授权前的验证
Vaccines (Basel). 2023 Aug 19;11(8):1386. doi: 10.3390/vaccines11081386.

本文引用的文献

1
Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials.母亲疫苗对母亲和婴儿有效且安全吗？随机对照试验的系统评价和荟萃分析。
BMJ Glob Health. 2023 Oct;8(10). doi: 10.1136/bmjgh-2023-012376.
2
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.呼吸道合胞病毒融合前 F 亚单位疫苗：首个保护婴儿的母体疫苗的批准。
Paediatr Drugs. 2023 Nov;25(6):729-734. doi: 10.1007/s40272-023-00598-3.
3
Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19.
儿童呼吸道合胞病毒：新冠疫情后的流行病学和临床影响。
Curr Opin Infect Dis. 2023 Dec 1;36(6):522-528. doi: 10.1097/QCO.0000000000000967. Epub 2023 Oct 13.
4
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
5
Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.两种用于预防呼吸道合胞病毒（RSV）疾病的疫苗（Arexvy和Abrysvo）。
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-156. doi: 10.58347/tml.2023.1686a.
6
Maternal RSV vaccine: Further analysis is urged on preterm births.孕妇呼吸道合胞病毒疫苗：敦促对早产情况进行进一步分析。
BMJ. 2023 May 10;381:1021. doi: 10.1136/bmj.p1021.
7
Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation.呼吸道合胞病毒：传播、病理生理学及表现的综合综述
Cureus. 2023 Mar 18;15(3):e36342. doi: 10.7759/cureus.36342. eCollection 2023 Mar.
8
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
9
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.一种二价呼吸道合胞病毒预融合F疫苗在老年人中的疗效和安全性
N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
10
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.在母亲及其婴儿中进行的一种呼吸道合胞病毒疫苗（RSVPreF3）的安全性和免疫原性的 2 期随机试验。
J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024.